Equities

Medicon Hellas SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MEDIC:ATH

Medicon Hellas SA

Actions
  • Price (EUR)2.56
  • Today's Change0.00 / 0.00%
  • Shares traded610.00
  • 1 Year change+12.28%
  • Beta0.6807
Data delayed at least 20 minutes, as of Feb 16 2026 15:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Medicon Hellas SA is a Greece-based company active in the health equipment sector. Its activities include research and development, production, and import and export of diagnostic products; the development of laboratory information systems; the import and distribution of in vitro diagnostics and automated analytical systems, such as Olympus for clinical chemistry, immunochemistry and lab automation, and Nihon Kohden for hematology, and the provision of cosmetic and body care products, such as make-up, anti-ageing and skin care products under the brand name Miss Beaute. Its laboratory information systems products include: Gi-Lab, which is a management system for medical laboratories; Gi-Maxima, a management program for medical centers, and Gi-Blood, which is an application that helps to connect various blood donation networks. On December 6, 2013, it merged by absorption of its subsidiary, Medicon Ltd.

  • Revenue in EUR (TTM)18.29m
  • Net income in EUR1.84m
  • Incorporated1988
  • Employees151.00
  • Location
    Medicon Hellas SAMelitona 5-7, GerakasATHINA 153 44GreeceGRC
  • Phone+30 2 106606000
  • Fax+30 2 106612666
  • Websitehttps://www.mediconsa.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SyntheticMR AB (publ)5.38m-5.18m9.43m41.00--0.678--1.75-0.9057-0.90570.94671.650.3678--0.87331,391,415.00-35.42-7.92-51.34-10.5110.4156.07-96.28-14.37---8.730.0450--2.473.20-241.50--7.37--
Observe Medical ASA1.49m-10.96m9.91m4.00--4.29--6.66-26.57-26.573.290.19090.11182.878.293,350,800.00-82.38-42.22-205.00-64.146.2430.17-737.14-327.970.1175-3.720.9572---33.85153.47-98.73---2.97--
Iconovo AB149.64k-3.89m9.98m19.00--0.4465--66.66-1.67-1.670.05372.460.0117--0.260863,475.20-30.39-28.39-33.14-31.51901.69159.24-2,598.41-295.86---138.020.0391---58.55-24.2210.36--22.28--
Rua Life Sciences PLC5.94m-977.48k10.17m33.00--1.24--1.71-0.0137-0.01370.08320.11510.54591.186.23---9.18---10.42--77.10---16.82--3.87--0.0995--------------
Genincode PLC3.35m-5.71m10.18m36.00--1.27--3.04-0.0232-0.02320.01370.00930.656215.742.8780,944.45-111.87---164.53--53.02---170.49--2.73-10.960.0669--25.05--36.80------
Arcoma AB12.54m410.30k10.25m31.0023.711.489.390.8180.32050.32059.875.131.452.9213.714,288,452.004.752.166.663.7540.4537.953.271.402.04--0.000.00-3.813.24336.0011.08-9.43--
Immunovia AB (publ)74.03k-11.84m11.28m9.00------152.36-0.3569-0.35690.0024-0.0210.0156--0.26487,222.22-249.16-48.08-827.53-52.27-7,231.59-6,932.30-15,989.68-17,625.510.6282-3.001.68---40.8921.2075.26------
Medicon Hellas SA18.29m1.84m11.31m151.006.130.59233.330.61860.41730.41894.144.320.56751.732.09126,136.605.526.006.477.0570.5372.889.739.82--292.260.3271--0.03046.158.4911.12-11.83--
Spineguard SA4.32m-2.56m11.74m15.00--1.88--2.72-0.0459-0.04590.07670.06640.49691.444.26196,474.10-29.46-27.72-45.24-47.3970.9873.78-59.29-59.200.8202-5.140.3472--7.77-7.4126.33--10.00--
Verici DX PLC1.61m-6.43m11.75m15.00--0.8987--7.28-0.023-0.0230.00580.00750.2298--1.6778,001.52-91.48---119.40--81.60---398.12------0.102--229.62--32.75------
BioMaxima SA14.41m154.02k12.69m126.0082.371.1412.460.88030.15480.154814.4811.160.79782.285.28481,976.200.852614.981.1119.2548.6941.641.0712.210.71061.480.2544--12.9612.06-8.70--6.75--
Laboratoires Euromedis SA38.40m-5.48m12.99m44.00--0.7752--0.3384-1.93-1.9313.515.830.90092.764.01872,683.60-12.988.24-17.9711.7826.7732.38-14.416.092.25-16.410.3414--6.39-14.02-146.59------
Genedrive PLC1.10m-6.02m13.02m43.00--4.78--11.87-0.0093-0.00930.00170.00230.1984--1.8022,186.05-108.81-77.52-153.92-106.30-----548.32-1,016.121.64--0.00--90.42-2.0726.06---10.48--
iZafe Group AB556.46k-1.67m13.03m10.00--8.39--23.42-0.0614-0.06140.01940.04520.17573.448.15843,000.00-52.78-57.76-73.42-72.44-106.29-287.24-300.41-630.900.9122-17.450.0198--336.55-11.1036.26---24.50--
Scandinavian Medical Solutions A/S32.86m3.48k13.10m28.005,333.331.1811.180.39880.00070.00078.882.991.291.9411.19--0.01376.590.024611.6823.1224.880.01064.680.35241.140.4345--8.2842.38-99.67-64.34----
Scandinavian Real Heart AB0.00-3.67m13.20m12.00--0.8386-----16.17-16.170.0016.690.00----0.00-44.53-27.49-52.77-30.65-------12,518.77----0.0678------49.47--6.59--
Data as of Feb 16 2026. Currency figures normalised to Medicon Hellas SA's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.